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Values	  are	  means±SEM.	  *	  p<0.05	  



































































K.	  Sutoh	  et	  al.	  BBB	  2006.	   Capsiate	  
Pal:	  phenylalanine	  ammonia	  lyase	  
Ca4H:	  cinnamic	  acid	  4-­‐hydroxylase	  
Ca3H:	  coumaric	  acid	  3-­‐hydroxylase	  
COMT:	  caﬀeic	  acid	  O-­‐methyltransferase	  
BCAT:	  Branched-­‐chain	  amino	  acid	  transferase	  
BKDH:	  3-­‐methyl-­‐2-­‐oxobutanoate	  dehydrogenase	  
FAT:	  acyl-­‐ACP	  thioesterase	  
KAS:	  β-­‐ketoacyl	  ACP	  synthase	  












Phenylalanine	   Valine	  
カプシエイト生合成をCSが触媒する	
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Thomas J. Moore 
Diet has hardly any effect on your cholesterol level; the 
drugs that can lower it often have serious or fatal side 
effects; and there is no evidence at all that lowering 
your cholesterol level will lengthen your life  
The Atlantic Monthly 1989 (Sept) pp 37-70 
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:P value  were adjusted by 




Change from Week 4 
p=0.0003 p 0.0001 
p 0.0001 

















Paticients: 125 hypercholesterolemia patients not achieving their LDL-C goals recommended JAS 2007 guideline, in addition failed to reach LDL-C<120mg/dL 
 after 10 mg atorvastatin monotherapy for 4 weeks 
Method:  Patients were randomized to 10mg ezetimibe 10mg atorvastatin, 20mg atorvastatin or 2.5mg rosuvastatin for 12 weeks. Changes in lipid 
 parameters and tolerability were assessed     
Safety  The incidence of drug-related adverse reactions were observed 8.5%(4/47) in 10mg ezetimibe 10mg atorvastatin group, 10.9%(5/46) in 20mg 
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Figure 1.  
  Study Design 
Week 
-8~-3
Week 12 Week 16 14 day
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Anacetrapib 300 mg 
Anacetrapib 10 mg
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Anacetrapib 40 mg 
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Anacetrapib 100 mg + Atorvastatin 10 mg
Anacetrapib 40 mg + Atorvastatin 10 mg












Protocol PN029 (05/22/09, DRAFT) 
Figure 3. Changes from Baseline in HDL-C over Time: (A) Anacetrapib Monotherapy vs. Placebo and (B) 
 Anacetrapib + Atorvastatin 10 vs. Atorvastatin 10 mg  
A.  
 
Figure 2. Changes from Baseline in LDL-C over Time: (A) Anacetrapib Monotherapy vs. Placebo and (B) 
 Anacetrapib + Atorvastatin 10 vs. Atorvastatin 10 mg 
A.  
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